ReviewClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2025
Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction.
Review in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Restoring the Airway Barrier: How Targeting Eosinophilic Inflammation Shapes Epithelial Health and Clinical Remission in Asthma.Diagnostics (Basel, Switzerland) · 2026Review
- Epithelial alarmins TSLP, IL-33, and IL-25 in asthma pathogenesis: mechanistic roles and therapeutic implications.Molecular biology reports · 2026Review
- Clinical Remission in Severe T2-High Asthma in Real Life After Anti-IgE, Anti-IL-5 and Anti-IL5R: A Potential Role for CRP as a Biomarker.Clinical and translational allergy · 2026Article
- Baseline Composite Score for 12-Month Clinical Remission in Biologic-Treated Severe Asthma: Development of the Base4Score.Biomedicines · 2026Article
- Early and Sustained Asthma Control and Remission in Real-World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC-2.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Observational
- Depemokimab and the twice-yearly regimen: pharmacological implications and therapeutic positioning in severe eosinophilic respiratory diseases.Frontiers in immunology · 2026Review
- Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms.Journal of inflammation research · 2026Review
- Clinical Remission in Patients with Severe Eosinophilic Asthma - A Single-Arm Observational Study with Benralizumab.Journal of asthma and allergy · 2026Article
- The Impact of Obesity on Airway Inflammation, Lung Function and Biologic Treatment in Asthma: A Narrative Review.Journal of inflammation research · 2026Review
- Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy.Frontiers in immunology · 2026Review
- Benralizumab-Induced Asthma Remission: Impact of Different Tools and Thresholds to Define Good Asthma Control.Respiration; international review of thoracic diseases · 2026Article
- Remission in Severe Asthma: Insights from Clinical Trials and Real-world Evidence on Response to Biologic Therapies.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of biologics, such as benralizumab (an anti-IL-5 receptor α humanised monoclonal antibody), has made remission a feasible goal for patients with severe eosinophilic asthma (SEA). However, there are remaining research gaps and no clear consensus on the definition of remission. We consolidated post hoc remission data from clinical trials and real-world studies of benralizumab in patients with SEA to gather insights on: testing different definitions; predictors of remission; the effect of comorbidities on achieving remission; remission and background medication reduction; long-term remission patterns with benralizumab; and remission in a real-life setting. In the SIROCCO and CALIMA Phase 3 randomised studies, patients with remission had higher baseline median blood eosinophil counts, were more likely to have a FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.